Get the Stockscreener App
34.11
1.79%
0.60
Ionis Pharmaceuticals Inc stock is traded at $34.11, with a volume of 1.40M.
It is up +1.79% in the last 24 hours and up +4.06% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$33.51
Open:
$33.84
24h Volume:
1.40M
Relative Volume:
0.85
Market Cap:
$5.43B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-11.22
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
+3.43%
1M Performance:
+4.06%
6M Performance:
-5.51%
1Y Performance:
-9.21%
1-Day Range:
$33.43
$34.36
1-Week Range:
$32.00
$34.36
52-Week Range:
$23.95
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
34.11 | 5.30B | 705.14M | -453.90M | -551.29M | -3.04 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report? - Yahoo Finance
We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed - simplywall.st
Transthyretin Amyloid Cardiomyopathy Treatment Market Deep Research ReportPfizer, Ionis Pharmaceuticals - openPR.com
Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Ionis Pharmaceuticals’ SWOT analysis: RNA therapeutics firm faces pivotal year for stock - Investing.com
Angioedema Treatment Market Insights and Forecast from 2025 - openPR.com
Hereditary Angioedema Drugs Market 2034: EMA, PDMA, FDA - openPR.com
Ionis’ olezarsen shows new promise with strong Phase III results - The Pharma Letter
December 2027 Options Now Available For Ionis Pharmaceuticals (IONS) - Nasdaq
Ionis reports success in olezarsen trial for high triglycerides - Yahoo
Treatment-Resistant Hypertension Market: Epidemiology, - openPR.com
Ionis Pharmaceuticals (NASDAQ:IONS) Earns Buy Rating from HC Wainwright - Defense World
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
Hereditary Angioedema Market Set to Grow Substantially Through - openPR.com
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Transcript : Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 08 - marketscreener.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Janus Henderson Group PLC - Defense World
Ionis reports positive data from study of olezarsen for hypertriglyceridemia - Clinical Trials Arena
Ionis Pharmaceuticals (IONS) Receives Buy Rating from HC Wainwri - GuruFocus
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14 Analysts - Benzinga
In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes - insights.citeline.com
Ionis reports positive results for olezarsen in study By Investing.com - Investing.com South Africa
Ionis reports positive results for olezarsen in study - Investing.com Australia
Olezarsen Cuts Triglyceride Levels at 6 Months in Essence Study - HCPLive
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides - BioSpace
Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Ionis Pharmaceuticals Says Olezarsen Trial Meets Primary Endpoint, All Key Secondary Endpoints - marketscreener.com
Ionis Pharmaceuticals (IONS) Reports Positive Results from Olezarsen Study | IONS Stock News - GuruFocus
Ionis announces positive topline results from Essence study of o - GuruFocus
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides | IONS Stock News - GuruFocus
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stake Reduced by Comerica Bank - Defense World
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Transcript : Ionis Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 09 - marketscreener.com
Familial Chylomicronemia Syndrome Drugs Market Size in 7MM - openPR.com
Polycythemia Vera Drugs Market Size in 7MM is expected to grow at - openPR.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential - Insider Monkey
Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential - Insider Monkey
Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - Yahoo Finance
Ionis to host 2025 virtual Annual Meeting of Stockholders | IONS Stock News - GuruFocus
Ionis to host 2025 virtual Annual Meeting of Stockholders - Business Wire
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts - Yahoo Finance
Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway - MSN
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):